Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labcorp HoldingsLTS:0JSY +1.86%80 Debt-to-Equity is 0.83 as of Mar. 2026, which is 1% above its 10-year median of 0.82. GuruFocus rates LTS:0JSY with a GF Score™ of 80/100 and a GF Value™ of $270.12 (Fairly Valued). The stock has 6 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Labcorp Holdings ranks worse than 78.14% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Labcorp Holdings's Debt-to-Equity or its related term are showing as below:
LTS:0JSY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.59 Med: 0.82 Max: 1.18
Current: 0.83
During the past 13 years, the highest Debt-to-Equity Ratio of Labcorp Holdings was 1.18. The lowest was 0.59. And the median was 0.82.
LTS:0JSY's Debt-to-Equity is ranked worse than 78.14% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs LTS:0JSY: 0.83
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Labcorp Holdings Debt-to-Equity Related Terms
Labcorp Holdings Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Labcorp Holdings's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0JSY vs DGX, GH, MTD: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Labcorp Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labcorp Holdings Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Labcorp Holdings's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Labcorp Holdings's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labcorp Holdings (LTS:0JSY) has a Debt-to-Equity of 0.83 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Labcorp Holdings and its competitors. This is near median its historical median of 0.82. Over the past decade, Labcorp Holdings' Debt-to-Equity has ranged from 0.59 to 1.18. According to the industry distribution chart, Labcorp Holdings ranks #143 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 78.1%.
Is Labcorp Holdings' Debt-to-Equity too high?
Labcorp Holdings' current Debt-to-Equity of 0.83 is near median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 1.18. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Labcorp Holdings' value of 0.83 is 151.5% above this industry median. Based on the distribution chart, Labcorp Holdings ranks #143 out of 183 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Labcorp Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labcorp Holdings' Debt-to-Equity compare to DGX and GH?
According to the Medical Diagnostics & Research industry distribution chart, Labcorp Holdings ranks #143 out of 183 companies for Debt-to-Equity. This places Labcorp Holdings in the lower half of its industry. The industry median Debt-to-Equity is 0.33. Labcorp Holdings' value of 0.83 is 151.5% above this benchmark. Historically, Labcorp Holdings' own Debt-to-Equity has ranged from 0.59 to 1.18 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 0.33, Labcorp Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labcorp Holdings's current Debt-to-Equity of 0.83 is 151.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Labcorp Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labcorp Holdings's current Debt-to-Equity is 0.83, which is near median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labcorp Holdings stock overvalued right now?
Based on GuruFocus' analysis, Labcorp Holdings (LTS:0JSY) is currently considered Fairly Valued. The stock's GF Value™ is $270.12, compared to a current price of $282.00 — trading 4.4% above its estimated fair value. The current Debt-to-Equity is 0.83, which is near median its 10-year median of 0.82 and 151.5% above the Medical Diagnostics & Research industry median of 0.33. Labcorp Holdings' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Labcorp Holdings (LTS:0JSY), the current Debt-to-Equity is 0.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labcorp Holdings (LTS:0JSY) Overvalued in 2026?
Based on GuruFocus' analysis, Labcorp Holdings stock appears to be overvalued.
The current stock price of $282.00 is trading 4.4% above its estimated GF Value™ of $270.12.
GuruFocus considers Labcorp Holdings to be Fairly Valued.
Key valuation signals for LTS:0JSY:
Debt-to-Equity: 0.83 (near median its 10-year median of 0.82)
GF Value™: $270.12 vs. price of $282.00 (4.4% above fair value)
Industry Position: 151.5% above the Medical Diagnostics & Research median (#143 of 183)
No single metric tells the full story. See the LTS:0JSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
80GF Score
Get the complete analysis for LTS:0JSY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JSY has been successfully added to your 
